☸️ SAIMSARA — Public Sessions

Stent retrievers are no longer just a device story; this review shows them as a full procedural ecosystem where aspiration strategy, device sizing, balloon-guide support, clot biology, and first-pass optimization shape real clinical success. The full read is valuable because it separates where stent-retriever thrombectomy is firmly evidence-based from where practice is still driven by anatomy, technique, emerging devices, and lower-certainty frontier applications.

Viabahn is not one device story but a whole vascular strategy: emergency bleeding control, femoropopliteal reconstruction, dialysis-access salvage, aneurysm exclusion, and complex aortic bridging all appear in the evidence map. The full review separates where Viabahn and VBX look durable from where patency depends heavily on anatomy, sizing, runoff, mobility zones, and antiplatelet planning.

Supera is not just another femoropopliteal stent story: the evidence shows a device whose success depends heavily on deployment precision, vessel preparation, lesion mechanics, and anatomical stress. The full review separates durable patency signals from real-world failure zones, including elongation, fracture, popliteal stress, dialysis-access uncertainty, and off-label use beyond the core femoropopliteal indication.

PCSK9 base editing is moving from experimental promise toward clinical reality, with single-dose therapies already producing durable LDL-C reductions in both primates and early human studies. The full evidence map reveals which delivery platforms, editing strategies, and safety signals are driving this transition—and where the remaining uncertainties still lie.

Surgery does not end when the operation ends: this review shows that across oncology, bariatrics, orthopedics, transplantation, and vascular care, postoperative medication adherence is often the hidden determinant of recurrence, complications, and survival. The full read is worth it because it separates where adherence reliably fails, which barriers drive that failure, and which interventions actually help keep patients on treatment after discharge.

Nicotine pouches sit at the centre of a public-health paradox: they may reduce toxicant exposure for adult smokers who fully switch, yet the evidence map shows rapid youth uptake driven by flavors, TikTok visibility, product appeal, and aggressive marketing. The full review separates harm-reduction promise from initiation risk, mapping 109 references across pharmacokinetics, oral safety, biomarkers, youth use, regulation, and the fast-moving nicotine-analogue market.

Giant cell myocarditis is rare, but the evidence map shows why it should never be treated as a diagnostic afterthought: survival depends on early biopsy, rapid combination immunosuppression, and timely escalation to mechanical support or transplantation. The full review distills 169 references into a practical map of prognosis, arrhythmia risk, cardiac sarcoidosis overlap, relapse surveillance, and the unresolved gaps that still shape real-world management.

Falsified medical products are not a niche drug-safety problem, but a supply-chain failure spanning medicines, devices, online pharmacies, informal markets, and weak regulatory systems. The full evidence map shows where risk concentrates — from semaglutide and PDE-5 products to vaccines, antibiotics, devices, and digital marketplaces — and which detection, reporting, and regulatory tools can realistically close the gaps.

Medical podcasts are no longer just convenient audio extras — this evidence map shows where they actually improve knowledge, confidence, clinical skills, CME behavior, and patient-facing communication, and where their impact remains limited. The full read separates strong educational signals from hype, including AI-generated podcasts, quality-transparency gaps, listener behavior, and the practical standards needed before podcasts can be trusted as serious medical-learning infrastructure.

Buttock augmentation safety is not defined by aesthetics alone: this evidence map shows that risk concentrates around where material is placed and what material is used, with subcutaneous image-guided fat grafting looking far safer than intramuscular injection or illicit permanent fillers. The full read separates low-complication fat-grafting and implant techniques from the dangerous edge cases — fat embolism, silicone embolism, septic shock, granulomatous hypercalcemia, sciatic nerve injury, and difficult filler migration — giving clinicians and patients a practical map of where buttock augmentation becomes unsafe.

Research automation is no longer a futuristic add-on — this review shows where it is already transforming science, from trial recruitment and evidence synthesis to laboratory workflows and multimodal data pipelines, often cutting manual work by more than 90% without sacrificing performance. Across 1,679 original studies, the paper maps not only where automation truly delivers speed, scale, and reproducibility, but also where human oversight remains the difference between safe acceleration and costly over-trust.

Remote robotic surgery is no longer science fiction: the evidence shows real feasibility across 5G telesurgery, neurovascular intervention, spine surgery, and remote mentoring, but only when latency, bandwidth, redundancy, cybersecurity, and feedback systems are treated as clinical safety infrastructure. The full evidence map shows where remote robotic surgery is already clinically credible, where it remains experimental, and which technical safeguards will determine whether distance-separated surgery becomes a safe medical service or only a technological demonstration.